Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous

Systemic Lupus Erythematous Clinical Trial

— CLOPUS  

Official title:

Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02320357
• Other study ID #: CHUBX 2013/27
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: December 16, 2014
• Last updated: October 23, 2017
• Start date: August 19, 2015
• Est. completion date: September 11, 2017

Study information

• Verified date: October 2017
• Source: University Hospital, Bordeaux
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

CD40 Ligand (CD40L) has been identified as a key feature in systemic lupus erythematosus (SLE) pathogenesis, a systemic autoimmune disease characterized by a multiorgan involvement. As platelets are a major source of soluble CD40L (sCD40L), we propose to study the effect of clopidogrel, a platelet inhibitor, on plasmatic sCD40L levels in SLE patients.

Description:

Type I interferon (IFN) and CD40L have been identified as important in SLE pathogenesis (1). CD40L is now considered as a biomarker of lupus activity (4). Because platelets represent a major reservoir of CD40L, we previously studied the role of platelet derived CD40L in SLE pathogenesis (5). We showed that platelets from SLE patients were activated in vivo by circulating immune complexes composed of autoantibodies bound to self antigens through a Fc-gamma Receptor IIa (CD32)-dependent mechanism. Further, platelet activation correlated with severity of the disease and activated platelets formed aggregates with antigen-presenting cells including monocytes and plasmacytoid dendritic cells. In addition, activated platelets enhanced IFN-α secretion by immune complexes-stimulated plasmacytoid dendritic cells in vitro through a CD154-CD40 interaction. In lupus prone mice, depletion of platelets or administration of the clopidogrel improved all measures of disease activity and overall survival. In this pilot study the treatment of the research is clopidogrel given at the dose of 75mg once a day. For the features of the treatment, its contraindications, its disruption in case of side effects cf to annex 1. Clopidogrel associated with the usual treatment of patients will be given for 12 weeks, the follow up of patients will be 16 weeks, all side effects occurring during this period will be recorded.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: September 11, 2017
• Est. primary completion date: September 11, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of SLE according to revised criteria of American College of Rheumatology

• Being affiliated to health insurance

• Having signed an informed consent (later than the day of inclusion and before any examination required by research)

Exclusion Criteria:

• > 20mg/day of prednisone equivalent for > 7 days 30 days before the pre-inclusion.

• Diseases flare 3 months before the inclusion. A disease flare is defined by an increase of SLEDAI score >3 and or a change of the immunosuppressive treatment and or an increase of steroids dose.

• Is treated or has received 3 months before the pre-inclusion steroids pulses or intravenous immunoglobulins.

• Renal involvement that could required a kidney biopsy.

• Required surgery in the next 12 weeks.

• Has been treated by cyclophosphamide 3 months before the pre-inclusion.

• Has been treated by biotherapy 6 months before the pre-inclusion.

• Contraindication to clopidogrel (annex 1).

• History of cancer except healed basal cell carcinoma.

• History of severe hemorrhage

• Disease exposing to hemorrhage

• Associated antiphospholipid syndrome

• Pregnant or breastfeeding women

• No contraception for women of childbearing age

• Severe hypertension

• Ongoing statin, non-steroidal anti-inflammatory, antiplatelet and anticoagulant drugs.

• Being under guardianship

• Patient participating at an other biomedical research with an exclusion period at the screening visit.

Related Conditions & MeSH terms

• Lupus Erythematosus, Systemic
• Systemic Lupus Erythematous

Intervention

Drug:
• Treatment by clopidogrel
Peripheral blood will be obtained during the study

Locations

Country	Name	City	State
France	Service de Médecine Interne et maladies Infectieuses - Hôpital Saint-André	Bordeaux
France	Service de Médecine Interne	Limoges
France	Service de Médecine Interne et Immunopathologie	Toulouse

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Bordeaux	Ministry for Health and Solidarity, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurements of plasmatic sCD40L levels		12 weeks afther the inclusion (D0)
Secondary	Measurements of plasmatic sCD40L levels		At 1 month before the inclusion (M-1) and at 24 hours, 7 days, 4, 8 and 16 weeks after the inclusion (D0)
Secondary	Measurements of IFN inducible genes by RT-PCR in circulating monocytes		At the inclusion (D0) and 12 weeks after the inclusion (D0)
Secondary	Measurements of platelet activation markers by flow cytometry		12 weeks afther the inclusion (D0)
Secondary	Measurements of platelet/circulating mononuclear cells aggregates by flow cytometry		At 7 days and 12 weeks after the inclusion (D0)
Secondary	Measurements of T lymphocytes activation by flow cytometry		At 7 days and 12 weeks after the inclusion (D0)
Secondary	Rate of haemorrhagic side effects during the follow up		At 24 hours, 7 days, 4, 8, 12 and 16 weeks after the inclusion (D0)
Secondary	Measurements of inflammation markers, antiantibodies levels, complement fractions		At 24 hours, 7 days, 4, 8, 12 and 16 weeks after the inclusion (D0)